Clinical features in different age groups of patients with autoimmune hepatitis

Experimental and Therapeutic Medicine

Volumn 7, Issue 1, 2013, Pages 145-148

  Peng, Milin ^a   Li, Yi ^a   Zhang, Min ^a   Jiang, Yongfang ^a   Xu, Yuan ^a   Tian, Yi ^a   Peng, Feng ^a   Gong, Guozhong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Autoimmune hepatitis; China; Clinical presentation; Concurrent autoimmune diseases

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CHINA; COMPARATIVE STUDY; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE;

EID: 84887965678     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1363     Document Type: Article

References (24)

1. Alvarez F, Berg PA, Bianchi FB, et al: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31: 929-938, 1999.
2. Seo S, Toutounjian R, Conrad A, et al: Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 23: 1410-1414, 2008.
3. Czaja AJ: Autoimmune liver disease. Curr Opin Gastroenterol19: 232-242, 2003.
4. Wiesner RH, Demetris AJ, Belle SH, et al: Acute allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28: 638-645, 1998.
5. Feld JJ, Dinh H, Arenovich T, et al: Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42: 53-62, 2005.
6. Czaja AJ: Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 51: 313-333, 2005.
7. Floreani A, Niro G, Rosa Rizzotto E, et al: Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 24: 1051-1057, 2006.
8. Parker DR and Kingham JG: Type I autoimmune hepatitis is primarily a disease of later life. QJM 90: 289-296, 1997.
9. Ichai P, Duclos-Vallée JC, Guettier C, et al: Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 13: 996-1003, 2007.
10. Johnson PJ and McFarlane IG: Meeting report: International Autoimmune Hepatitis Group. Hepatology 18: 998-1005, 1993.
11. Ngu JH, Gearry RB, Frampton CM, et al: Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 55: 522-529, 2012.
12. Hoeroldt B, McFarlane E, Dube A, et al: Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 140: 1980-1989, 2011.
13. Manns MP, Woynarowski M, Kreisel W, et al: Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139: 1198-1206, 2010.
14. Al-Chalabi T, Underhill JA, Portmann BC, et al: Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 6: 1389-1395, 2008.
15. Ngu JH, Gearry RB, Frampton CM and Stedman CA: Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study. Hepatology 57: 2399-2406, 2013.
16. Czaja AJ and Carpenter HA: Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 43: 532-538, 2006.
17. Miyake Y, Iwasaki Y, Takaki A, et al: Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis. Intern Med 46: 1945-1949, 2007.
18. Czaja AJ: Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 30: 394-401, 1999.
19. Baeres M, Herkel J, Czaja AJ, et al: Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut51: 259-264, 2002.
20. Zauli D, Ghetti S, Grassi A, et al: Anti-neutrophil cytoplasmic antibodies in type 1 and type 2 autoimmune hepatitis. Hepatology 25: 1105-1107, 1997.
21. Czaja AJ, Donaldson PT and Lohse AW: Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 97: 413-419, 2002.
22. Toda G, Zeniya M, Watanabe F, et al: Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 26: 1207-1212, 1997.
23. Czaja AJ and Freese DK; American Association for the Study of Liver Disease: Diagnosis and treatment of autoimmune hepatitis. Hepatology 36: 479-497, 2002.
24. Krawitt EL: Autoimmune hepatitis. N Engl J Med 354: 54-66, 2006.